AstraZeneca Considering Merger with Bristol Myers Squibb, Report Says
According to a Financial Times report, UK-based pharmaceutical company AstraZeneca is exploring a potential merger with U.S.-based competitor Bristol Myers Squibb. If finalized, the deal would create one of history's largest mergers, forming a combined entity valued at approximately $400 billion. The companies have been in discussions for several months, though it remains uncertain whether the deal will proceed. Both AstraZeneca and Bristol Myers Squibb declined to comment on the matter when contacted by CNBC. The potential merger would significantly reshape the pharmaceutical industry landscape due to its scale and strategic implications across key therapeutic areas such as oncology. Bristol Myers Squibb has a history of aggressive acquisition strategies, including recent purchases that have bolstered its position in cancer treatments.
Topics: Corporate Strategy Market Consolidation Pharmaceuticals